Venous thromboembolism in chronic gastrointestinal disorders
Expert Rev Gastroenterol Hepatol. 2022 May 3:1-12. doi: 10.1080/17474124.2022.2072295. Online ahead of print.ABSTRACTINTRODUCTION: Chronic gastrointestinal disorders (including autoimmune gastritis, celiac disease, inflammatory bowel disease, and diverticular disease) are highly prevalent disorders, that may be associated with unpredictable, life-threatening complications, such as thromboembolic events. Venous thromboembolism (VTE) is one of the major causes of morbidity and mortality worldwide. Several conditions, including cancer, major trauma, surgery, prolonged immobilization, are well-established risk factors for VTE....
Source: Expert Review of Gastroenterology and Hepatology - May 3, 2022 Category: Gastroenterology Authors: Federica Melazzini Francesca Calabretta Marco Vincenzo Lenti Antonio Di Sabatino Source Type: research

The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center
CONCLUSIONS: In this study of real-world data, the median OS and PFS for all patients with mPDAC were equivalent before and after incorporating newer treatment regimens into the clinical practice.PMID:35400291 | DOI:10.1080/17474124.2022.2065259 (Source: Expert Review of Gastroenterology and Hepatology)
Source: Expert Review of Gastroenterology and Hepatology - April 11, 2022 Category: Gastroenterology Authors: Moataz Ellithi Mohamed Abdallah McKenna Fischer Isaak Ailts John Fanta Kate Waligoske Matthew Bell Morgan E Nelson Jonathan Bleeker Source Type: research

A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
Expert Rev Gastroenterol Hepatol. 2022 Apr 11. doi: 10.1080/17474124.2022.2065258. Online ahead of print.ABSTRACTINTRODUCTION: Ozanimod is a sphingosine-1-phosphate (S1P) modulator that inhibits lymphocyte trafficking from lymph nodes to the circulation. It is approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing multiple sclerosis and most recently for the management of moderate-severe ulcerative colitis (UC).AREAS COVERED: Here we review the status of drugs approved for moderate-severe UC, the unmet needs in the management of UC, proposed mechanisms of action of S1P modulators, clinical data ...
Source: Expert Review of Gastroenterology and Hepatology - April 11, 2022 Category: Gastroenterology Authors: Roni Aoun Stephen Hanauer Source Type: research

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339. doi: 10.1080/17474124.2022.2064273. Epub 2022 Apr 10.ABSTRACTINTRODUCTION: Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Recent years have seen the emergence of novel systemic treatments for HCC patients, including immune checkpoint inhibitors (ICIs). Nonetheless, several questions regarding HCC immunotherapy remain unanswered, especially in terms of biochemical predictors of response.AREAS COVERED: In the current paper, we will discuss available evidence regarding p...
Source: Expert Review of Gastroenterology and Hepatology - April 11, 2022 Category: Gastroenterology Authors: Alessandro Rizzo Antonio Cusmai Gennaro Gadaleta-Caldarola Gennaro Palmiotti Source Type: research